INTRODUCTION
Alkaline phosphatases (EC 3.1.3.1) are dimeric enzymes that are present in most organisms 1 , in which they catalyze the hydrolysis of phosphomonoesters. In humans, three of the four isozymes are tissue specific: intestinal (IAP), placental (PLAP) and germ cell (GCAP) APs. The fourth alkaline phosphatase is tissue nonspecific (TNAP) and is expressed in bone, liver and kidney 2 . Recent studies have provided compelling evidence that a major role of TNAP in bone tissue is to hydrolyze extracellular inorganic pyrophosphate (PP i ), a powerful inhibitor of mineralization, thus ensuring normal bone mineralization 2 . These studies suggest that TNAP may be an attractive therapeutic target for the treatment of calcification disorders.
Identification of small-molecule effectors of TNAP not only may lead to the therapeutic treatment of disorders in which the involvement of TNAP is unambiguously documented, but also may provide invaluable research tools to study the potential role of TNAP in diverse physiological and pathological conditions. Even though the enzyme has been known for many decades, its mechanism of action in diverse biological processes is still unclear and is being actively investigated 2 . Many phosphocompounds have been documented as substrates of TNAP, including p -nitrophenyl phosphate (pNPP), α -naphthylphosphate, β -glycerophosphate, phosphoserine, PP i , pyridoxal-5 ′ -phosphate (PLP), phosphothreonine, phosphotyrosine, phosphatidates, polyphosphates, ATP, ADP, AMP, glucose-1-phosphate, glucose-6-phosphate and fructose-6-phosphate 2 . However, only two -PP i and PLP -have been unequivocally confirmed as physiological substrates of TNAP, as abnormalities in their metabolism explain the phenotypic changes of hypophosphatasia, a genetic disease resulting from TNAP deficiency 3 -5 . In vitro reaction of TNAP shows significant rate acceleration in the presence of amino-containing alcohols functioning as phosphate-acceptor substrates in transphosphorylation reactions. The physiological role of this reaction is unknown, and it is unclear which, if any, metabolite could be functioning as a natural transphosphorylation agent. Thus, there is an unmet need for chemical tools that could help in explaining the physiological role of TNAP in normal and pathological states.
To make the assay sensitive to the influence of TNAP effectors with diverse modes of action (MOAs), we based the assay optimization on knowledge of the TNAP reaction mechanism ( Fig. 1 ). The molecular mechanism of alkaline phosphatase catalysis is common to the enzyme in various species and tissues 6 . The initial alkaline phosphatase -catalyzed (E in Fig. 1 ) reaction consists of a substrate (DO-P i )-binding step, phosphate-moiety transfer to the active-site serine residue, and product alcohol (DOH) release. In the second part of the reaction, phosphate is released through hydrolysis of the covalent intermediate (E-P i ) and through dissociation of inorganic phosphate (P i ) from the noncovalent complex (E · P i ). In the presence of amino-containing alcohol molecules (AOH), P i is also released through a faster transphosphorylation reaction branch.
Alkaline phosphatase assays commonly used in clinical practice 7 (see also WHO Guidelines on Standard Operating Procedures for Clinical Chemistry, Section B http://www.searo.who.int/EN/ Section10/Section17/Section53/Section481_1761.htm ) are based on dephosphorylation of pNPP (see its structure in Fig. 2a ) in the presence of high concentrations of an amino-containing buffer, such as 2-amino-2-methyl-1-propanol or diethanolamine (DEA).
High-throughput screening of tissue-nonspecific alkaline phosphatase for identification of effectors with diverse modes of action
Here we describe a protocol for the identification of effectors of tissue-nonspecific alkaline phosphatase (TNAP). It is based on a highly sensitive method for detecting TNAP activity. After dephosphorylation by TNAP, a dioxetane-based substrate undergoes a series of chemical transformations resulting in light production. Light intensity serves as a quantitative measure of the velocity of the TNAP-catalyzed reaction in the steady state. This protocol includes guidelines for optimizing the assay and for high-throughput screening in multiwell plates. The assay is sensitive to the influence of diverse effectors of TNAP as long as the assay optimization steps are repeated for each new batch of the enzyme; full optimization is accomplished in under 2 d. Depending on the available equipment, 10,000 -100,000 compounds can be screened in an 8-h period. This protocol provides a method of screening TNAP that is 1,000-fold more sensitive and 10-fold faster than a conventional colorimetric assay with p -nitrophenyl phosphate.
Figure 1 | Catalytic mechanism of alkaline phosphatase reaction 11 . E, alkaline phosphatase enzyme molecule; P i , inorganic phosphate; DO-P i , substrate molecule; E-P i , phosphoenzyme (enzyme phosphorylated on Ser 93 in the TNAP sequence of its active site); DOH, product alcohol; E · P i , noncovalent complex of inorganic phosphate in the active site; AOH, an alcohol molecule (acceptor substrate of transphosphorylation reaction); AO-P i , product of transphosphorylation reaction.
Besides maintaining alkaline pH, amino-containing buffers also serve as substrates for the alkaline phosphatase transphosphorylation reaction that are present at their saturating levels. Assays of this type are very easy and inexpensive to perform. However, colorimetric detection of the product on the basis of its absorbance at 405 nm results in significant optical interference from library collections. Many small molecules absorb light in the range of wavelengths used in the assay. In addition, the specific activity of TNAP measured by colorimetry is low, necessitating the use of high concentrations of the enzyme in the assay. Such excessive enzyme concentrations can be partially counteracted by extended incubations of the reaction mixture to promote accumulation of p -nitrophenol product. Although the high stability of TNAP permits incubation for several days, a slow spontaneous hydrolysis of pNPP in aqueous solutions and evaporation of solutions should be taken into account when selecting the appropriate incubation time. After incubation, absorbance in the plate can be assessed either right away or after stopping the reaction. The latter approach also permits storing the plates for some time (for example, overnight) before measuring the signal.
To date, all inhibitors available for TNAP, as for all other mammalian alkaline phosphatases, are uncompetitive in nature. They include some amino acids, such as l -homoarginine 8 , as well as some unrelated compounds, such as levamisole 9 and theophylline 10 . These known inhibitors of TNAP are not entirely specific for this alkaline phosphatase isozyme, have low affinity and are not particularly good at inhibiting the pyrophosphatase activity of TNAP.
The protocol described here has been successfully used for a high-throughput screening (HTS) campaign 11 . It allows the identification and confirmation of TNAP effectors with diverse MOAs 11, 12 . During this campaign, the novel TNAP assay was implemented and optimized. The assay uses a luminescence detection method based on CDP-Star, a 1,2-dioxetane -based substrate (see its structure in Fig. 2b ) that was invented and commercialized for detection of alkaline phosphatases in blotting applications 13, 14 . The overall chemical reaction is a cascade of consecutive steps triggered by alkaline phosphatasecatalyzed dephosphorylation of the substrate ( Fig. 3a ) . This initial step leads to the generation of an unstable product that decomposes to a stable product with concomitant light production in the lower portion of the visible spectrum ( Fig. 3b ) . At the Conrad Prebys Center for Chemical Genomics (CPCCG) (formerly known as the San Diego Center for Chemical Genomics and the Burnham Center for Chemical Genomics), this detection method was successfully implemented as a homogeneous HTS assay for alkaline phosphatase activity 11 . This approach is very robust and fast, as the exact determination of alkaline phosphatase steady-state velocity, which is proportional to the light intensity at any given moment, can be accomplished within minutes for an entire 384-or 1,536-well plate.
This assay was applied to and optimized for TNAP screening. The concentrations of enzymes, substrates and buffer components were adjusted to achieve maximal assay sensitivity. Subsequent HTS and follow-up studies led to the identification of several potent and selective chemical series targeting TNAP and showing diverse MOA properties 11 . The luminescence-based TNAP assay is ~ 1,000-fold more sensitive than the colorimetric assay, and thus requires much lower concentration of TNAP protein. The high sensitivity of the assay enabled structure-activity relationship studies conducted at CPCCG, which led to the identification of a 5-nM inhibitor of TNAP
12
. In addition to superior sensitivity, the luminescence-based assay has a 100-fold wider dynamic range than the colorimetric assay, making it applicable for detection of inhibitors and activators of TNAP in a single screening campaign. A minor drawback of the luminescence-based assay is the transient nature of luminescence. Photons cannot be ' stored ' or accumulated and must be detected at the time of their generation. Stability of the signal output in the luminescence assay over a period of more than 5 h neutralizes this shortcoming, as luminescence can be measured at any point during this time without loss of signal.
Experimental design
The sensitivity of a functional assay is defined by the degree of an enzyme ' s saturation with its substrates. It is common knowledge that competitive inhibitors show diminished potency in the presence of high substrate concentrations, whereas uncompetitive inhibitors have maximal potency at the saturation level of the substrate. In our experiments, we set substrate concentrations to match their respective K m values; these conditions are optimally suited for identification of various classes of inhibitors. The kinetic parameters of the luminescent TNAP reaction were determined for both CDP-Star and DEA substrates. Experimental data for CDP-Star and DEA substrates concentration optimization are shown in Figures 4 and 5 , respectively. The data were analyzed by nonlinear regression using the Michaelis -Menten equation:
where v is the steady-state rate of the enzymatic reaction, S the concentration of the corresponding substrate, V max maximal velocity of the reaction and K m the Michaelis constant of the studied substrate S. The concentration of the enzyme is another important parameter of an assay that contributes to its sensitivity. Initial velocity of an enzymatic reaction is directly proportional to enzyme concentration. Departure from a steady state, such as rapid consumption of substrate in the presence of high enzyme concentration, results in a deviation from the linearity of the reaction (as seen in Fig. 6 ). The lower limit of the enzyme concentration is determined by nonenzymatic processes responsible for the assay background. The separation between the highest and lowest enzyme concentrations detectable in an assay defines its dynamic range. The data for the optimization of TNAP concentration in the assay described here are shown in Figure 6 . The limit of detection (LOD) of the assay is calculated using the following formula:
where σ is the standard deviation of the blank samples without TNAP and Slope is the slope of the corresponding calibration curve activity versus enzyme concentration. The LOD value provides a quantitative measure of assay sensitivity and is equal to the minimal concentration of enzyme that can be reliably distinguished from the background. The actual LOD values, and thus the concentration of the enzyme necessary for screening, depend on the sensitivity of a plate reader available at a particular laboratory. The selection of the enzyme concentration with respect to the LOD value determines the assay robustness and its performance in HTS. A concentration of enzyme that is at least 20-fold over the LOD is normally selected for screening; higher concentrations of the enzyme are preferred, as they usually provide better assay performance.
Assay performance is quantified using a Z ′ -factor that is calculated according to the formula reported by Zhang et al. 15 : (3) where μ + and μ − are mean values and σ + and σ − are standard deviations of the positive (fully inhibited enzyme) and negative (uninhibited enzyme) control wells of the plate, respectively. The Z ′ -factor is linked to the concentration of the enzyme in the assay. For the TNAP concentration optimization experiment ( Fig. 6 ), the Z ′ -factor has values above 0.5 corresponding to [TNAP] / LOD > 20 and reaches its maximal value at [TNAP] ≈ 150 × LOD. Knowledge of the optimal time point for the data acquisition and dimethyl sulfoxide (DMSO) tolerance of the assay is also required for a successful HTS campaign. In the luminescence assay, TNAP is insensitive to DMSO concentrations ≤ 2 % . We determined that the luminescent signal in the TNAP reaction reaches its steady-state output 15 min after initiation of the reaction and is stable over at least 5 h. Extended life of the luminescent signal is an important characteristic of the assay, as it allows the assay to be performed on a luminescent plate reader at any reading speed.
To validate the sensitivity of the assay after completing its optimization, we tested the effect of levamisole, a known inhibitor of TNAP, on the enzyme ' s activity ( Fig. 7 ) . Levamisole inhibited TNAP with an IC 50 (concentration of half-maximal inhibition) value equal to 20 μ M. This value is almost identical to one previously obtained using the colorimetric pNPP-based assay 16 . Other alkaline phosphatases are not sensitive to levamisole inhibition. Thus, applications of the luminescence-based screening process to other mammalian alkaline phosphatase isozymes would require the substitution of levamisole with other, more appropriate isozymeselective inhibitors as controls, such as l -phenylalanine for IAP and PLAP, l -leucine for GCAP and others 1, 2 . In the final validation stage, assay performance was tested in the desired plate format and using the same reagents, materials, equipment and liquid-handling techniques as would be used during the HTS stage ( Fig. 8 ).
The Z ′ -factor equal to 0.76 attested that the assay was robust and HTS ready.
The final concentrations of the components of the fully optimized TNAP assay were as follows: 100 mM DEA (pH 9.8), 1.0 mM MgCl 2 , 0.02 mM ZnCl 2 , 50 μ M CDP-Star and 2 % (vol / vol) DMSO. Positive control wells contained 1 mM levamisole; negative control wells contained 2 % DMSO. Compounds were added to the appropriate wells at a 20 μ M concentration. Compound efficacy was estimated after data conversion to percent inhibition: where NC and PC represent the average values of negative and positive control wells, respectively, and Y the value observed in a well with the tested compound.
The protocol described in this article can be easily adapted to different plate densities (1,536, 384 or 96 wells) and diverse liquid-handling and screening equipment. In a low-throughput mode, the assay could be performed using 8-or 12-channel pipettes. For HTS, specialized liquid-handling equipment is required. Making intermediate-dilution compound plates is sometimes necessary to ensure that the DMSO concentration in the assay is kept below its tolerance limit. Library compounds are dissolved in 100 % DMSO, and thus maintaining its concentration in the assay at 1 -2 % requires nanoliter to low-microliter dispense volumes attainable only with specialized screening instrumentation. Use of inter mediate-dilution plates allows compound dispensing with common liquid-handling equipment without surpassing the DMSO tolerance limit. Extended stability of the assay reagents enabled us to run the assay in batches of multiple plates. The throughput of the primary screening assay could be easily adjusted and, depending on laboratory-specific equipment and resources, may vary from several compounds to > 100,000 compounds a day.
The same HTS assay is used for confirmation and characterization of the ' hits ' (compounds that demonstrate properties of interest) identified in primary screening. Compounds are either cherry-picked from source plates or taken from ' daughter ' (intermediate-dilution) plates containing partial DMSO -aqueous compound solutions. If intermediate-dilution plates are used, in light of lower compound stability in aqueous solutions, it might be beneficial to perform the reconfirmation step on the day of compound dilution and screening. Low hit rates observed in TNAP screening (described in the ANTICIPATED RESULTS) make this a feasible arrangement. In addition, the HTS reagents could be prepared in excess and used for hit confirmation on the same or next day without loss of performance.
The dose-response confirmation performed at the CPCCG is based on a twofold serial dilution of compounds in 100 % DMSO. We use ten-point dose-response curves in duplicate for each compound tested. In a 384-well format, columns 1 -2 and 23 -24 are reserved for positive and negative controls, respectively. Data are analyzed using nonlinear regression and fitted to the Hill equation:
where [C] is compound concentration in micromolar units, IC 50 is the concentration value of half-maximal inhibition, also in micromolar units, and n H is the Hill coefficient of the curve. The protocol described in this article is amenable and was successfully applied at the CPCCG to the screening of three isozymes of alkaline phosphatases (one of them from two sources) (PubChem AIDs 518, 690, 1017 and 1019; http://pubchem.ncbi.nlm.nih.gov/ assay/assay.cgi?aid=518&loc=ea_ras , http://pubchem.ncbi.nlm. nih.gov/assay/assay.cgi?aid=690&loc=ea_ras , http://pubchem. ncbi.nlm.nih.gov/assay/assay.cgi?aid=1017&loc=ea_ras and http:// pubchem.ncbi.nlm.nih.gov/assay/assay.cgi?aid=1019&loc=ea_ras ). At different stages, screening was performed using diverse instrumentation, ranging from bulk dispensers (as described in this article) to a fully automated ultra-HTS system. The protocol ' s application to TNAP screening is described in more detail in the ANTICIPATED RESULTS. 
REAGENT SETUP
᭡ CRITICAL The assay performed as described below requires 3,072 and 64 l of the enzyme/substrate and 10 % DMSO / levamisole hydrochloride working solutions, respectively. Prepare enough reagents for the screening of 1.5 times the number of actual plates. This excess is necessary to offset the unusable ( ' dead ' ) volumes associated with the operation of liquid dispensers. In addition, the remaining solutions will be used to repeat the plates with suboptimal performance and could be used for confi rmation of the primary hits the same or next day. All the working solutions, including TNAP, CDP-Star, levamisole and 10 % DMSO, are stable at room temperature (18 -25 ° C) for several days with no signifi cant loss of performance. However, one should exercise caution and avoid unnecessary use of aged solutions, as prolonged storage at ambient temperatures could affect the enzyme ′ s stability and thus its response to compounds.
Buffers and solutions Prepare the following solutions:
High-DEA buffer containing 1 M DEA (pH 9.8), 1 mM MgCl 2 , 0.02 mM ZnCl 2 . Store at room temperature for several days.
No-DEA buffer containing 25 mM N -cyclohexyl-3-aminopropanesulfonic acid (pH 9.8), 1 mM MgCl 2 , 0.02 mM ZnCl 2 . Store at room temperature for several days.
Assay buffer containing DEA concentration equal to 2.5 × K m(DEA) (pH 9.8), 2.5 mM MgCl 2 and 0.05 mM ZnCl 2 . Store at room temperature for several days.
TNAP working solution that contains 2.5 times the desired TNAP concentration in the assay buffer. Fresh solution is prepared on the day of the screening. Store at room temperature for several days.
CDP-Star working solution that contains its concentration equal 2.5 × K m(CDP-Star) in Milli-Q water. Store at room temperature for several days.
Levamisole hydrochloride working solution is 5 mM in 10 % DMSO. The solution is prepared on the day of screening from a 50 mM levamisole solution in DMSO stored at − 80 ° C. Store at room temperature for several days. Compound library Stocks of the compounds to be tested are prepared by dissolving each compound in DMSO to a concentration of 1 mM. Compounds that do not readily dissolve should be sonicated during the solvation stage.
PROCEDURE Optimization of buffer conditions of TNAP luminescent reaction • TIMING 1 -2 d 1|
Determine the activity of TNAP in high-DEA buffer in the presence of varied concentrations of CDP-Star substrate (for example, between 0 and 500 μ M). Activity of TNAP is equal to the luminescent light intensity at the steady state of the overall reaction; because of a lag phase in the detection step, the steady state is normally achieved after 15 -20 min. Analyze the data and determine the K m(CDP-Star) value according to equation 1 through nonlinear regression using an appropriate curve-fi tting software product such as GraphPad Prism, as seen in Figure 4 .
2| Determine the activity of TNAP in No-DEA buffer containing CDP-Star at the concentration equal to its K m value in the presence of varied DEA substrate concentration. Analyze the data and determine the K m(DEA) value according to equation 1 using nonlinear regression within an appropriate curve-fi tting software such as GraphPad Prism, as seen in Figure 5 . ᭡ CRITICAL STEP It is imperative to determine the K m values of substrates carefully. Triplicate or quadruplicate data points provide more reliable results. Fig. 6 ) in the presence of CDP-Star and DEA concentrations equal to their respective K m values determined in Steps 1 and 2. Calculate LOD using equation 2 . ᭡ CRITICAL STEP It is important to determine the LOD and the range of rate linearity for TNAP carefully. The concentration of the enzyme relative to the LOD value of the assay determines the assay performance. The minimal concentration of TNAP in the assay is 20 × LOD.
3| Determine TNAP concentration ([TNAP])-dependent activity (

4|
Validate the assay performance using the conditions determined in Steps 1 -3. Obtain the activity of TNAP within positive and negative control conditions, each replicated in multiple wells. Calculate the Z ′ -factor using equation 3 . Assay validation can be combined with an expanded version of Step 3, as shown in Figure 6 . In this case, the plate is added with serially diluted TNAP in the working buffer, such that each concentration of TNAP occupies 2 -4 columns. Buffer without TNAP is also included as a part of the experiment. The reaction is initiated by adding CDP-Star working solution to the whole plate. This experiment allows simultaneous determination of the LOD for TNAP and Z ′ -factor values for different concentrations of TNAP, making the selection of the appropriate TNAP concentration for HTS easy. 14| Add 8 μ l of TNAP working solution to all the wells of each plate using the Thermo Matrix WellMate bulk dispenser.
High-throughput screening assay
15|
Briefl y centrifuge the plates and incubate them for 30 min at room temperature.
16|
Measure luminescence using an EnVision plate reader (PerkinElmer) in the whole batch of prepared plates.
17| Determine the Z ′ -factor of each plate using equation 3.
18|
Reject the data for the plates with Z ′ -factors below 0.5, and repeat the screening of the plates.
19|
Calculate percentage inhibition in each well using equation 4.
20| Identify ' hits ' that meet cutoff criteria (for example, show ≥ 50 % inhibition). PAUSE POINT Hit confirmation can be performed on the day of screening or on the following day.
NATURE PROTOCOLS | VOL.5 NO.8 | 2010 | 1437 TNAP hit confirmation • TIMING 0.5 -1 d 21| Cherry-pick hits (that is, select them for retesting and pick them from the plates either manually or using an automated pipetting system) and dilute them appropriately to obtain 100 μ M solution containing 10 % DMSO. ᭡ CRITICAL STEP If this step is performed on the same day as the HTS, the intermediate-dilution plates from Step 5 can be used. ? TROUBLESHOOTING Troubleshooting advice can be found in Table 1 . 
22|
ANTICIPATED RESULTS
This protocol describes a novel homogeneous assay for TNAP and its application in HTS. During the implementation stage, the protocol is optimized for a particular alkaline phosphatase preparation to identify the most sensitive and reliable screening conditions. The screening portion of the protocol effi ciently captures TNAP effectors and separates them from rare false positives. Only the compounds identifi ed as hits in both the primary HTS and the cherry-picking confi rmation stages proceed to further characterization. Optimization of substrate and enzyme concentrations lays the foundation for assay sensitivity; thus, accurate determination of K m values for the substrates is very important. Too high or too low a concentration of TNAP can lead to erroneous results. For example, if the signal in the presence of saturating concentrations of CPD-Star and / or DEA (see Figs. 4 and 5 ) is less than tenfold the signal obtained in the absence of the corresponding substrate, a higher concentration of TNAP should be used. However, too high a concentration of TNAP would result in premature substrate consumption, leading to reduced activity and signifi cant decline of signal over time.
In the absence of a priori knowledge of enzyme preparation activity and its affi nity to substrates, it is helpful to go through a couple of cyclic reiterations of Steps 1 -3 to ensure that both enzyme and substrate concentrations are optimally adjusted. Alternatively, substrate-dependent activity can be measured in the presence of different concentrations of TNAP to provide enzyme concentration -independent values of K m along with enzyme-dependent curves for each substrate concentration.
Results anticipated from enzyme-dependent experiments are shown in Table 2 . Background activity inherent to the reaction in the absence of enzyme is used as a positive control for the reaction. Average and standard deviation values determined for each TNAP concentration from all replicate wells are used to calculate Z ′ -factor values. Similar to this experiment, Z ′ -factor is also determined at the assay validation stage ( Fig. 8 ) and during HTS.
We found that the luminescent CDP-Star -based reaction provided much higher sensitivity and required much less enzyme than the commonly used colorimetric assay. The luminescence assay also provided a much broader dynamic range, enabling us to monitor both inhibition and activation of the enzyme simultaneously.
Using the described protocol at CPCCG, we successfully screened TNAP activity against a collection of 64,000 compounds. The average Z ′ -factor for the full screen was 0.82, with values ranging from 0.75 to 0.89. From the primary screen, 73 primary positives ( ' hits ' ) were identifi ed, resulting in a 0.11 % hit rate. Primary HTS hits were retested in single-concentration mode and 55 primary hits were reconfi rmed. Further characterization of the hits led to the identifi cation of 53 compounds with concentration-dependent inhibition and IC 50 values below 20 μ M. The results of the screening are summarized in Table 3 . This high percentage of reconfi rmation attests to the robustness and reliability of the assay.
As a result of screening, multiple chemical series of both the inhibitors and activators were identifi ed. Attesting to the assay ' s sensitivity, these included CDP-Star -competitive and -uncompetitive inhibitor classes 12, 17 . The former were identifi ed for alkaline phosphatases for the fi rst time 12 . The inhibitors of both classes were active in HTS assay conditions, but were characteristically affected by varied concentrations of CPD-Star: IC 50 values of competitive and uncompetitive inhibitors increased and decreased, respectively, concomitant with an increase in CDP-star concentration. The chemical series were also diverse with respect to the DEA substrate and contained representatives of both competitive and noncompetitive classes 12, 17 . The fact that hits identifi ed through the screening have such diverse mechanistic properties confi rms that the assay is sensitive to compounds with diverse MOA. The full account of the TNAP HTS campaign and follow-up studies conducted at CPCCG is provided elsewhere 11 . The protocol described in this article is applicable for assay optimization and for the HTS of various alkaline phosphatases. At the CPCCG, the protocol was used for three alkaline phosphatases and led to their successful HTS campaigns. Although the protocol specifi cally describes screening performed in 384-well plates, it could be easily adapted to screening in 96-or 1,536-well plates by increasing the volume 2.5-fold or by reducing the volume 4-fold, respectively. At the CPCCG, we successfully performed additional TNAP and IAP screening (against a library of 200,000 compounds) in 1,536-well plates.
Although we described use of some specifi c instrumentation in the protocol, it could be easily substituted with analogous instruments without compromising assay performance. Optimization of the assay according to the instrumentation available in a screening laboratory will ensure its successful application for identifi cation of TNAP and other alkaline phosphatase effectors. As discussed above, application of the screening to other mammalian alkaline phosphatase isozymes would require the substitution of levamisole with other, more appropriate isozyme-selective inhibitors as controls 1, 2 .
